2000
Advanced Glycosylation Endproducts and Diabetic Vascular Disease
Bucala R. Advanced Glycosylation Endproducts and Diabetic Vascular Disease. Developments In Cardiovascular Medicine 2000, 224: 287-303. DOI: 10.1007/978-1-4615-4649-8_15.Peer-Reviewed Original ResearchDiabetic vascular diseaseVascular diseaseAtherosclerotic vascular diseaseClinical pharmacological studiesProgressive vasculopathyOverall morbidityMicrovascular diseaseAnatomic typesPersistent hyperglycemiaDiabetic complicationsEtiologic roleAdvanced glycosylation endproductsBiochemical abnormalitiesDiabetic sequelaeNon-enzymatic glycosylationPharmacological studiesUnderlying causeDiseaseCapillary bedComplicationsBasic laboratoryVasculopathyMorbidityHyperglycemiaRetinopathy
1998
Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit
Panagiotopoulos S, O'Brien R, Bucala R, Cooper M, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998, 136: 125-131. PMID: 9544739, DOI: 10.1016/s0021-9150(97)00192-5.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsAortic archAbdominal aortaAdvanced glycationPlaque formationVasculopathy of diabetesAnti-atherogenic effectsHigh-cholesterol dietCholesterol-fed rabbitsDevelopment of atherosclerosisDegree of atheromaCholesterol dietAortaAtheromaRabbitsThoracicAminoguanidineDosesGlycationTreatmentArchAge levelsNon-enzymatic interactionVasculopathySudan IV
1995
Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDisease